Literature DB >> 9872194

The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis.

P L Ho1, K N Chan, M S Ip, W K Lam, C S Ho, K Y Yuen, K W Tsang.   

Abstract

STUDY
OBJECTIVE: To investigate the effect of Pseudomonas aeruginosa infection on clinical parameters in Chinese patients with noncystic fibrosis and steady-state bronchiectasis.
DESIGN: Prospective, cross-sectional clinicomicrobiological study with informed consent.
SETTING: Consecutive outpatient recruitment from a specialist bronchiectasis respiratory clinic. PATIENTS: Outpatients (n = 100; 62 women; 55.1+/-16.7 years old; FEV1/FVC 1.4+/-0.7/2.1+/-0.9 L), who had stable respiratory symptoms for more than 3 weeks. MEASUREMENTS AND
RESULTS: Respiratory pathogens isolated from the sputum were: Pseudomonas aeruginosa (33), Haemophilus influenzae (10), Moraxella catarrhalis (2), other Gram-negative bacilli (5), Streptococcus pneumoniae (6), Staphylococcus aureus (5), mycobacteria (3), and yeast (1). Clinical parameters in patients with positive isolation of P aeruginosa were compared with those without the organism in the sputum culture (non-P aeruginosa). In the P aeruginosa group, the FEV1/FVC ratio and sputum volume were lower (p < 0.005) and higher (p < 0.0001), respectively, than those of the non-P aeruginosa group. The FEV1/FVC ratio (< 60%) and sputum volume (grading > 5) were independently associated with a positive sputum isolation of P aeruginosa with odds ratios of 3.1 (confidence interval [CI] 1.2 to 8.4; p < 0.01) and 4.7 (CI 1.6 to 13.3; p < 0.001), respectively.
CONCLUSIONS: P aeruginosa is the predominant respiratory pathogen isolated in the sputum of Chinese patients with steady-state bronchiectasis, and its isolation is associated with high sputum output (> or = 75th quartile) and moderately severe airflow obstruction (FEV1/FVC < 60%).

Entities:  

Mesh:

Year:  1998        PMID: 9872194     DOI: 10.1378/chest.114.6.1594

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  30 in total

1.  Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors.

Authors:  J Angrill; C Agustí; R de Celis; A Rañó; J Gonzalez; T Solé; A Xaubet; R Rodriguez-Roisin; A Torres
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Inhaled fluticasone in bronchiectasis: a 12 month study.

Authors:  K W Tsang; K C Tan; P L Ho; G C Ooi; J C Ho; J Mak; G L Tipoe; C Ko; C Yan; W K Lam; M Chan-Yeung
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

Review 4.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Effect of airway Pseudomonas aeruginosa isolation and infection on steady-state bronchiectasis in Guangzhou, China.

Authors:  Wei-Jie Guan; Yong-Hua Gao; Gang Xu; Zhi-Ya Lin; Yan Tang; Hui-Min Li; Zhi-Min Li; Jin-Ping Zheng; Rong-Chang Chen; Nan-Shan Zhong
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

6.  Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.

Authors:  Timothy R Aksamit; Anne E O'Donnell; Alan Barker; Kenneth N Olivier; Kevin L Winthrop; M Leigh Anne Daniels; Margaret Johnson; Edward Eden; David Griffith; Michael Knowles; Mark Metersky; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Betsy Carretta; Charles L Daley
Journal:  Chest       Date:  2016-11-23       Impact factor: 9.410

7.  N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa.

Authors:  Tiemei Zhao; Youning Liu
Journal:  BMC Microbiol       Date:  2010-05-12       Impact factor: 3.605

Review 8.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 9.  The pathophysiology of bronchiectasis.

Authors:  Paul T King
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29

10.  Relationships between high-resolution computed tomography, lung function and bacteriology in stable bronchiectasis.

Authors:  Jin-Hwa Lee; Yoo-Kyung Kim; Hyon-Ju Kwag; Jung-Hyun Chang
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.